Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies

Ads

You May Also Like

Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences

DUBLIN, Ireland, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced ...

ASTRAZENECA’S FASLODEX MET PRIMARY ENDPOINT IN FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER

AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500mg ...